News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Previously, the use of the drug was limited to patients requiring hospitalization
Subscribe To Our Newsletter & Stay Updated
